Company Overview
Snapshot
Founded in December 2010 by Boaz Assaf, Colospan operates with 11–50 employees. The company has raised $17M across 3 funding rounds from 6 investors. In June 2026, Colospan was acquired by Galmed Pharmaceuticals.
Business overview
Colospan is a clinical-stage medical device company focused on developing proprietary technology for colorectal surgery. The company's core product, CG-100, is a single-use, temporary intraluminal bypass device designed to prevent anastomotic leaks and divert colonic stomas. Colospan serves the healthcare industry, specifically targeting surgeons and hospitals with solutions for gastrointestinal procedures.
Strategic signal
In June 2026, Galmed Pharmaceuticals announced the acquisition of Colospan, restructuring the terms to prioritize CG-100 European commercialization and shareholder value protection. This acquisition positions Galmed to address a significant market with Colospan's FDA Breakthrough Device-Designated technology, indicating a strategic move to integrate innovative medical devices into a broader GI-focused platform.
Log in to access full profile ›Company Intelligence Q&A
- What was the most recent significant corporate event for Colospan?
- In June 2026, Colospan was acquired by Galmed Pharmaceuticals. The transaction was restructured to prioritize the European commercialization of Colospan's CG-100 product.
- When did Colospan receive FDA approval for its intraluminal bypass device?
- In January 2020, Colospan announced FDA approval of an Investigational Device Exemption (IDE) for its intraluminal bypass device, offering an alternative approach to diverting stoma.
- Which hospital was the first in the U.S. to test Colospan's CG-100 device?
- In December 2020, Henry Ford Hospital became the first in the U.S. to test Colospan's novel CG-100 intraluminal device in patients undergoing colorectal anastomosis.
- Did Colospan receive funding from the European Innovation Council?
- In December 2021, Colospan received funding from the European Innovation Council for its novel colorectal surgery device.
- Which investors participated in Colospan's September 2017 funding round?
- In September 2017, Colospan received funding from investors including Anatomy Medical Technology Fund.